<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04041843</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC 191</org_study_id>
    <nct_id>NCT04041843</nct_id>
  </id_info>
  <brief_title>Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism</brief_title>
  <acronym>VTE</acronym>
  <official_title>A Pilot Study of an Oral Anticoagulant &quot;Apixaban&quot; for theTreatment of Venous Thromboembolism in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a
      secondary thromboembolism.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>venous thromboembolism (VTE) formation</measure>
    <time_frame>7-90 days</time_frame>
    <description>No new VTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Doppler ultrasound vein imaging</measure>
    <time_frame>day 8-15</time_frame>
    <description>Change in VTE on Doppler ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Abixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg who have been diagnosed with a thrombosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg</description>
    <arm_group_label>Abixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adolescents with a newly diagnosed primary VTE.

          -  Treatment with apixaban has to begin within 72 hours of the diagnosis of VTE.

          -  Patients who have received heparin at the beginning of their diagnosis and are willing
             to switch to apixaban, are allowed to do so within 72 hours of their treatment.
             Patients who are switched to apixaban are not allowed to receive any other systemic
             anticoagulant therapy.

          -  VTE confirmed by diagnostic imaging.

          -  Children with body weight of ≥ 40 kg and are able to tolerate medication by mouth or
             administered via an NG or GT tube.

          -  Adequate liver function: AST and/or ALT &lt;5 times ULN, and/or Direct bilirubin &lt;2 times
             ULN

          -  Platelet count of at least ≥ 30,000/ul.

          -  Adequate renal function: &gt;30% of GFR for age

          -  Female subjects of childbearing potential must not be nursing or pregnant with
             negative urine pregnancy test within 72 hours prior to dosing with study medication.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Current or recent (within 3 months) apixaban administration.

          -  Patient is unable to tolerate medications by oral route or by n/g administration,
             peptic ulcer disease, intestinal obstruction, toxic megacolon, typhlitis, or short gut
             syndrome.

          -  History of primary bleeding disorder and first degree family history of bleeding
             disorder.

          -  Active bleeding or high risk of bleeding at the time of study entry.

          -  History of significant head injury and/or any history of intracranial hemorrhage.

          -  Conditions predispose to intracranial bleed; e.g. brain tumor, brain metastasis.

          -  Uncontrolled Grade 3 or 4 severe hypertension.

          -  History of allergy to apixaban or factor Xa inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oya Tugal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erin Morris, RN</last_name>
    <phone>(714) 964-5359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oya Tugal, MD</last_name>
    <phone>(914) 594-2134</phone>
    <email>oya_tugal@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harshini Mahanti, BBTech, MSCR</last_name>
      <phone>360-362-9008</phone>
      <email>harshini_mahanti@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Neida Otero, CRA</last_name>
      <phone>(914) 594-2146</phone>
      <email>neida.Otero@wmchealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

